Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Atea Pharmaceuticals (AVIR) Shares Outstanding (2019 - 2026)

Atea Pharmaceuticals' Shares Outstanding history spans 8 years, with the latest figure at $80.0 million for Q1 2026.

  • Quarterly Shares Outstanding fell 6.49% to $80.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $80.0 million through Mar 2026, down 6.49% year-over-year, with the annual reading at $78.1 million for FY2025, 7.5% down from the prior year.
  • Shares Outstanding came in at $80.0 million for Q1 2026, up from $78.1 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $85.6 million in Q1 2025 to a low of $78.1 million in Q3 2025.
  • The 5-year median for Shares Outstanding is $83.4 million (2023), against an average of $82.8 million.
  • The largest YoY upside for Shares Outstanding was 1.61% in 2025 against a maximum downside of 7.5% in 2025.
  • Atea Pharmaceuticals' Shares Outstanding stood at $83.3 million in 2022, then grew by 0.18% to $83.4 million in 2023, then increased by 1.23% to $84.5 million in 2024, then dropped by 7.5% to $78.1 million in 2025, then grew by 2.43% to $80.0 million in 2026.
  • Per Business Quant, the three most recent readings for AVIR's Shares Outstanding are $80.0 million (Q1 2026), $78.1 million (Q4 2025), and $78.1 million (Q3 2025).